E. Ohman J or Asset Management AB Sells 81,208 Shares of Terns Pharmaceuticals, Inc. $TERN

E. Ohman J or Asset Management AB decreased its holdings in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) by 79.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 21,202 shares of the company’s stock after selling 81,208 shares during the period. E. Ohman J or Asset Management AB’s holdings in Terns Pharmaceuticals were worth $857,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. Commodore Capital LP acquired a new position in shares of Terns Pharmaceuticals during the third quarter valued at about $42,807,000. Vanguard Group Inc. raised its holdings in shares of Terns Pharmaceuticals by 5.9% in the 3rd quarter. Vanguard Group Inc. now owns 4,559,917 shares of the company’s stock worth $34,245,000 after acquiring an additional 253,751 shares during the last quarter. Geode Capital Management LLC lifted its position in Terns Pharmaceuticals by 3.8% in the 2nd quarter. Geode Capital Management LLC now owns 1,633,349 shares of the company’s stock valued at $6,094,000 after acquiring an additional 59,145 shares in the last quarter. Adage Capital Partners GP L.L.C. acquired a new position in Terns Pharmaceuticals during the 2nd quarter valued at about $4,774,000. Finally, Franklin Resources Inc. acquired a new position in Terns Pharmaceuticals during the 2nd quarter valued at about $4,765,000. 98.26% of the stock is owned by institutional investors.

Terns Pharmaceuticals Stock Performance

Shares of NASDAQ:TERN opened at $52.86 on Thursday. The company has a market capitalization of $5.48 billion, a P/E ratio of -51.32 and a beta of -0.31. The company’s 50-day moving average is $40.63 and its 200 day moving average is $28.57. Terns Pharmaceuticals, Inc. has a fifty-two week low of $1.87 and a fifty-two week high of $52.98.

Trending Headlines about Terns Pharmaceuticals

Here are the key news stories impacting Terns Pharmaceuticals this week:

• Positive Sentiment: Merck agreed to an all-cash acquisition at $53.00 per share, approved by both boards and structured as a tender offer with expected closing in Q2 2026 — the deal provides a clear near-term valuation floor and validates Terns’ lead asset, TERN-701, as strategically valuable to a large pharma buyer. Read More.
• Positive Sentiment: Major media and wire services emphasize the strategic fit (adding a CML allosteric BCR::ABL1 inhibitor) and Merck’s broader push to refill its oncology pipeline ahead of Keytruda’s patent cliff — reinforcing deal rationale for investors. Read More.
• Neutral Sentiment: HC Wainwright reaffirmed a “neutral” rating with a $53 price target (essentially aligned with the offer price), suggesting limited upside beyond the transaction price while the deal closes. Read More.
• Neutral Sentiment: Deal mechanics: transaction is a tender offer contingent on shareholder participation and customary closing conditions — market will watch vote/acceptance levels, regulatory review and timing rather than Terns’ standalone clinical milestones. Read More.
• Negative Sentiment: Multiple shareholder-law firms have launched investigations into whether Terns’ board obtained a fair price (Monteverde, Ademi, Halper Sadeh), which could lead to litigation, delay or pressure on deal terms — a risk for timing and transaction certainty. Read More. Read More. Read More.

Insider Activity

In other news, CEO Amy L. Burroughs sold 14,583 shares of the firm’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $46.71, for a total transaction of $681,171.93. Following the completion of the sale, the chief executive officer owned 288,976 shares in the company, valued at $13,498,068.96. This trade represents a 4.80% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Emil Kuriakose sold 1,155 shares of Terns Pharmaceuticals stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $38.57, for a total transaction of $44,548.35. Following the completion of the sale, the insider directly owned 50,365 shares in the company, valued at $1,942,578.05. This trade represents a 2.24% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 170,409 shares of company stock worth $6,563,769. Insiders own 1.50% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently commented on TERN. Wall Street Zen downgraded Terns Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Jefferies Financial Group reaffirmed a “buy” rating and set a $70.00 target price on shares of Terns Pharmaceuticals in a research report on Wednesday, December 10th. Citigroup reiterated an “outperform” rating on shares of Terns Pharmaceuticals in a report on Wednesday, November 26th. Oppenheimer raised their price objective on Terns Pharmaceuticals from $28.00 to $58.00 and gave the company an “outperform” rating in a research note on Tuesday, December 9th. Finally, Mizuho lifted their price objective on shares of Terns Pharmaceuticals from $33.00 to $54.00 and gave the stock an “outperform” rating in a report on Tuesday, December 9th. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $57.33.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.